CCNY

Summary

CCNY (cyclin Y, HGNC:23354) is a protein-coding gene on chromosome 10p11.21, encoding Cyclin-Y (Q8ND76). Positive regulatory subunit of the cyclin-dependent kinases CDK14/PFTK1 and CDK16.

Cyclins, such as CCNY, control cell division cycles and regulate cyclin-dependent kinases (e.g., CDC2; MIM 116940) (Li et al., 2009 [PubMed 18060517]).

Source: NCBI Gene 219771 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 47 total — 1 pathogenic
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_145012

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23354
Approved symbol	CCNY
Name	cyclin Y
Location	10p11.21
Locus type	gene with protein product
Status	Approved
Aliases	CFP1, CBCP1
Ensembl gene	ENSG00000108100
Ensembl biotype	protein_coding
OMIM	612786
Entrez	219771

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 15 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000265375, ENST00000339497, ENST00000374704, ENST00000374706, ENST00000465416, ENST00000470025, ENST00000490012, ENST00000492478, ENST00000493157, ENST00000497692, ENST00000890615, ENST00000937098, ENST00000937099, ENST00000937100, ENST00000937101, ENST00000944714, ENST00000944715, ENST00000944716, ENST00000944717

RefSeq mRNA: 5 — MANE Select: NM_145012 NM_001282852, NM_001282853, NM_001282854, NM_145012, NM_181698

CCDS: CCDS60513, CCDS7189, CCDS7190

Canonical transcript exons

ENST00000374704 — 10 exons

Exon	Start	End
ENSE00000699510	35566023	35566185
ENSE00003484744	35525964	35525999
ENSE00003504291	35483404	35483478
ENSE00003537914	35516523	35516623
ENSE00003602824	35501501	35501535
ENSE00003620817	35529973	35530030
ENSE00003639482	35553019	35553185
ENSE00003684674	35530124	35530243
ENSE00003847065	35336509	35337207
ENSE00003847135	35569054	35572667

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 99.76.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 45.3705 / max 365.8299, expressed in 1822 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104683	28.5974	1816
104684	11.2506	1791
104685	3.5503	1518
104682	1.7356	1229
104681	0.2366	4

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.76	gold quality
left testis	UBERON:0004533	99.05	gold quality
right testis	UBERON:0004534	99.03	gold quality
testis	UBERON:0000473	97.88	gold quality
cardiac muscle of right atrium	UBERON:0003379	97.60	gold quality
left ventricle myocardium	UBERON:0006566	97.34	gold quality
monocyte	CL:0000576	97.21	gold quality
leukocyte	CL:0000738	97.10	gold quality
kidney epithelium	UBERON:0004819	96.97	gold quality
ventricular zone	UBERON:0003053	96.83	gold quality
upper arm skin	UBERON:0004263	96.81	gold quality
prefrontal cortex	UBERON:0000451	96.61	gold quality
stromal cell of endometrium	CL:0002255	96.31	gold quality
embryo	UBERON:0000922	96.12	gold quality
ganglionic eminence	UBERON:0004023	96.12	gold quality
epithelial cell of pancreas	CL:0000083	96.03	gold quality
calcaneal tendon	UBERON:0003701	95.82	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.64	gold quality
tendon	UBERON:0000043	95.50	gold quality
anterior cingulate cortex	UBERON:0009835	95.29	gold quality
islet of Langerhans	UBERON:0000006	95.21	gold quality
spinal cord	UBERON:0002240	95.14	gold quality
amygdala	UBERON:0001876	95.03	gold quality
nipple	UBERON:0002030	94.91	gold quality
frontal cortex	UBERON:0001870	94.89	gold quality
tendon of biceps brachii	UBERON:0008188	94.85	gold quality
myocardium	UBERON:0002349	94.82	gold quality
neocortex	UBERON:0001950	94.79	gold quality
oviduct epithelium	UBERON:0004804	94.76	gold quality
lower lobe of lung	UBERON:0008949	94.66	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	31.74
E-HCAD-35	yes	18.56
E-ANND-3	yes	9.38
E-HCAD-13	yes	8.19

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYC

miRNA regulators (miRDB)

165 targeting CCNY, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834

Literature-anchored findings (GeneRIF, showing 18)

• Single nucleotide polymorphism in CCNY gene is associated with Crohn’s disease and ulcerative colitis (PMID:18438405)
• CCNY might play an important role in glioma tumorigenisis. (PMID:20441050)
• these results validated the role of CCNY as a clinically relevant human oncoprotein (PMID:21273179)
• CCNY binding to CDK16 required a region upstream of the kinase domain and was found to be inhibited by phosphorylation of serine 153, a potential PKA phosphorylation site. (PMID:22184064)
• Cyclin Y regulates the expression and membrane trafficing of PCTAIRE kinases (PCTK). (Review) (PMID:22895054)
• Human cyclin Y (CCNY) is a phosphoprotein in vivo and phosphorylation of CCNY by CDK14 triggers its ubiquitination and degradation. (PMID:24794231)
• Our findings highlight a PFTK1-CCNY complex in activating noncanonical Wnt signaling in HCC cells. (PMID:24824184)
• Activation of PCTAIRE-1 is mediated through interaction with the phosphorylated form of cyclin Y in complex with 14-3-3. (PMID:26205494)
• CCNY was significantly upregulated in ovarian cancer cell lines and tissues. Significant association was observed between CCNY expression and clinicopathological stage and lymph node metastasis. It significantly exacerbated proliferation, migration, and invasion of A2780 cells, in vitro and in nude mice. It significantly increased c-Myc, cyclin D1, PFTK1, ki67, and OGT protein expressions in xenograft tumor tissues. (PMID:26831658)
• we believe that CCNY has biological effect in breast cancer (BC) development, and its inhibition via an RNA interference lentiviral system may provide a therapeutic option for BC (PMID:27666310)
• findings revealed an unrecognized role of Caprin-2 in facilitating LRP5/6 constitutive phosphorylation at G2/M through forming a quaternary complex with CDK14, Cyclin Y, and LRP5/6. (PMID:27821587)
• Amplification of gene CCNY is associated with metastatic lung adenocarcinoma. (PMID:28381877)
• increased expression of CCNY was significantly associated with cell proliferation and migration. (PMID:29557391)
• Fisetin inhibits TET1 expression and reduces 5hmC modification in specific loci in the promoters of CCNY/CDK16 in HuRSCs. (PMID:30411496)
• Cyclin Y and CDK16 complex is necessary for efficient AMPK-dependent activation of autophagy.This functional interaction is mediated by AMPK phosphorylating Serine 326 of Cyclin Y. (PMID:32098961)
• Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling. (PMID:33039146)
• Cyclin Y is expressed in Platelets and Modulates Integrin Outside-in Signaling. (PMID:33153214)
• The role of cyclin Y in normal and pathological cells. (PMID:36576166)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccny	ENSDARG00000063677
mus_musculus	Ccny	ENSMUSG00000024286
rattus_norvegicus	Ccny	ENSRNOG00000018123
drosophila_melanogaster	CycY	FBGN0032378
caenorhabditis_elegans		WBGENE00022697

Paralogs (2): CCNYL1 (ENSG00000163249), CCNYL1B (ENSG00000284209)

Protein

Protein identifiers

Cyclin-Y — Q8ND76 (reviewed: Q8ND76)

Alternative names: Cyclin box protein 1, Cyclin fold protein 1, cyclin-X

All UniProt accessions (3): Q8ND76, R4GN48, R4GNF3

UniProt curated annotations — full annotation on UniProt →

Function. Positive regulatory subunit of the cyclin-dependent kinases CDK14/PFTK1 and CDK16. Acts as a cell-cycle regulator of Wnt signaling pathway during G2/M phase by recruiting CDK14/PFTK1 to the plasma membrane and promoting phosphorylation of LRP6, leading to the activation of the Wnt signaling pathway. Recruits CDK16 to the plasma membrane. Isoform 3 might play a role in the activation of MYC-mediated transcription.

Subunit / interactions. Found in a complex with CAPRIN2, LRP6 and CDK14 during G2/M stage; CAPRIN2 functions as a scaffold for the complex by binding to CCNY via its N terminus and to CDK14 via its C terminus. Interacts with CDK14. Interacts with CDK16. Interacts with LRP6.

Subcellular location. Cell membrane Nucleus.

Tissue specificity. Widely expressed.

Post-translational modifications. Ubiquitinated; leading to its degradation. Heavily phosphorylated. Phosphorylation at Ser-71 and Ser-73 by CDK14 is enhanced during the G2 and M cell cycle phases, and creates a phosphodegron triggering SCF-dependent ubiquitination.

Similarity. Belongs to the cyclin family. Cyclin Y subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8ND76-1	1, b	yes
Q8ND76-2	2, a
Q8ND76-3	3

RefSeq proteins (5): NP_001269781, NP_001269782, NP_001269783, NP_659449, NP_859049 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006671	Cyclin_N	Domain
IPR012399	Cyclin_Y	Family
IPR013763	Cyclin-like_dom	Domain
IPR036915	Cyclin-like_sf	Homologous_superfamily

Pfam: PF00134

UniProt features (35 total): modified residue 19, sequence conflict 8, splice variant 2, mutagenesis site 2, initiator methionine 1, chain 1, domain 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9R2I	ELECTRON MICROSCOPY	3.3
9R2N	ELECTRON MICROSCOPY	3.83

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8ND76-F1	78.76	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (20): 73, 75, 83, 99, 100, 102, 280, 288, 295, 324, 326, 331, 2, 21, 25, 30, 33, 37, 67, 71

Mutagenesis-validated functional residues (2):

Position	Phenotype
2	induces a diffuse cytoplasmic localization.
3	no effect on subcellular location.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 212 (showing top): AAGCAAT_MIR137, GOBP_REGULATION_OF_AUTOPHAGY, GOBP_REGULATION_OF_PHOSPHORYLATION, MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GOBP_MALE_GAMETE_GENERATION, AAAYRNCTG_UNKNOWN, GOMF_KINASE_ACTIVATOR_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS

GO Biological Process (8): G2/M transition of mitotic cell cycle (GO:0000086), spermatogenesis (GO:0007283), positive regulation of autophagy (GO:0010508), Wnt signaling pathway (GO:0016055), positive regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045737), cell division (GO:0051301), regulation of canonical Wnt signaling pathway (GO:0060828), regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0000079)

GO Molecular Function (3): cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538), protein kinase binding (GO:0019901), protein binding (GO:0005515)

GO Cellular Component (7): cyclin-dependent protein kinase holoenzyme complex (GO:0000307), cytoplasmic cyclin-dependent protein kinase holoenzyme complex (GO:0000308), nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cyclin-dependent protein serine/threonine kinase activity	3
nuclear lumen	2
cellular anatomical structure	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G2/M phase transition	1
developmental process involved in reproduction	1
male gamete generation	1
autophagy	1
positive regulation of catabolic process	1
regulation of autophagy	1
cell surface receptor signaling pathway	1
regulation of cyclin-dependent protein serine/threonine kinase activity	1
positive regulation of cell cycle	1
positive regulation of protein serine/threonine kinase activity	1
positive regulation of cyclin-dependent protein kinase activity	1
cellular process	1
regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of protein serine/threonine kinase activity	1
cyclin-dependent protein kinase regulator activity	1
kinase binding	1
binding	1
serine/threonine protein kinase complex	1
cyclin-dependent protein kinase holoenzyme complex	1
cytoplasm	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

588 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCNY	CDK14	O94921	992
CCNY	CDK16	Q00536	916
CCNY	CCNB3	Q8WWL7	858
CCNY	CDK15	Q96Q40	743
CCNY	CDK5	Q00535	676
CCNY	CDK18	Q07002	550
CCNY	CDK17	Q00537	549
CCNY	CAPRIN2	Q6IMN6	548
CCNY	LRP6	O75581	524
CCNY	CCNC	P24863	502
CCNY	CCNL2	Q96S94	495
CCNY	FZD8	Q9H461	489
CCNY	CREM	Q03060	459
CCNY	CCNK	O75909	459
CCNY	MYC	P01106	455

IntAct

64 interactions, top by confidence:

A	B	Type	Score
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
CDK16	CCNY	psi-mi:“MI:0915”(physical association)	0.660
KIFAP3	KIF3C	psi-mi:“MI:0914”(association)	0.640
ABCD4	ABCD4	psi-mi:“MI:0914”(association)	0.640
GYPA	TCAF2	psi-mi:“MI:0914”(association)	0.640
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
CCNY	YWHAG	psi-mi:“MI:0915”(physical association)	0.590
YWHAG	CCNY	psi-mi:“MI:0915”(physical association)	0.590
YWHAE	SRSF10	psi-mi:“MI:0914”(association)	0.560
CCNY	YWHAH	psi-mi:“MI:0915”(physical association)	0.560
CCNY	CDK14	psi-mi:“MI:0915”(physical association)	0.540
CDK14	CCNY	psi-mi:“MI:0915”(physical association)	0.540
CDK14	CCNY	psi-mi:“MI:0403”(colocalization)	0.540
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
FYTTD1	UBA6	psi-mi:“MI:0914”(association)	0.530
HOXB5	VPS37C	psi-mi:“MI:0914”(association)	0.530
ATG3	MAP1LC3B2	psi-mi:“MI:0914”(association)	0.530
GJB7	PALM3	psi-mi:“MI:0914”(association)	0.530
GPR141	STXBP3	psi-mi:“MI:0914”(association)	0.530
CCNL2	ZBTB43	psi-mi:“MI:0914”(association)	0.530
TMEM185A	TSPAN6	psi-mi:“MI:0914”(association)	0.530
CYP51A1	POTEI	psi-mi:“MI:0914”(association)	0.530
HIDE1	GSDME	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
CCNY	LRRC59	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (85): CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS), CCNY (Affinity Capture-MS)

ESM2 similar proteins: A0A7H0DN99, A0A8V8TMC4, D3YUJ3, I2HAA0, O01501, O13818, O14260, O14332, O17657, O42575, O43008, P06776, P0C7X3, P17214, P25009, P30645, P34624, P36034, P38729, P52924, P53053, P53124, Q03080, Q05930, Q07788, Q08C99, Q08CI4, Q09792, Q10326, Q10PQ9, Q22695, Q28EL0, Q4R871, Q5IBH7, Q5ICL9, Q5MJ70, Q5T2Q4, Q5U5D0, Q6NRF4, Q75D04

Diamond homologs: A0A8V8TMC4, A6NIR3, D3YUJ3, P0C7X3, P34624, Q08CI4, Q28EL0, Q4R871, Q5T2Q4, Q5U5D0, Q5VUJ5, Q5VW22, Q6NRF4, Q8BGU5, Q8N7R7, Q8ND76, Q96P64, A1L520, A5PK26, O74345, O75689, O80925, O82171, O94601, O97902, P35197, P38682, P40529, Q04412, Q09531, Q0WQQ1, Q10165, Q10367, Q14161, Q15027, Q15057, Q17R07, Q1AAU6, Q1ZXH8, Q28CM8

SIGNOR signaling

10 interactions.

A	Effect	B	Mechanism
CCNY	up-regulates	CDK14	binding
AMPK	“up-regulates activity”	CCNY	phosphorylation
CDK14	“down-regulates quantity by destabilization”	CCNY	phosphorylation
CyclinY/CDK14	“down-regulates quantity by destabilization”	CCNY	phosphorylation
CDK1	“down-regulates activity”	CCNY	phosphorylation
CCNY	“form complex”	CyclinY/CDK16	binding
CCNY	“form complex”	CyclinY/CDK14	binding
PRKAA1	“up-regulates activity”	CCNY	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 83 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	6	93.2×	3e-09
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	82.3×	4e-09
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	6	82.3×	4e-09
Activation of BH3-only proteins	6	60.8×	2e-08
RHO GTPases activate PKNs	7	45.3×	8e-09
Intrinsic Pathway for Apoptosis	6	35.9×	6e-07
Translocation of SLC2A4 (GLUT4) to the plasma membrane	9	28.4×	3e-09
SARS-CoV-1-host interactions	6	21.5×	1e-05

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	24.1×	1e-03
intracellular protein localization	7	9.6×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	35
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
59701	GRCh38/hg38 10p11.21(chr10:34686264-35684215)x3	Pathogenic

SpliceAI

3679 predictions. Top by Δscore:

Variant	Effect	Δscore
10:35337204:GACG:G	donor_gain	1.0000
10:35337207:GGT:G	donor_loss	1.0000
10:35337208:G:GG	donor_gain	1.0000
10:35337209:T:G	donor_loss	1.0000
10:35434217:GGCT:G	donor_gain	1.0000
10:35434218:GCTG:G	donor_gain	1.0000
10:35483398:TTAAA:T	acceptor_loss	1.0000
10:35483399:TAAA:T	acceptor_loss	1.0000
10:35483400:AAAG:A	acceptor_loss	1.0000
10:35483401:A:G	acceptor_gain	1.0000
10:35483402:A:AC	acceptor_loss	1.0000
10:35483402:A:G	acceptor_gain	1.0000
10:35483403:G:GG	acceptor_gain	1.0000
10:35483474:GGACG:G	donor_gain	1.0000
10:35483475:GACGG:G	donor_gain	1.0000
10:35483477:CGG:C	donor_loss	1.0000
10:35483479:G:GG	donor_gain	1.0000
10:35483479:G:T	donor_loss	1.0000
10:35483480:T:A	donor_loss	1.0000
10:35530121:CA:C	acceptor_loss	1.0000
10:35530122:A:AC	acceptor_loss	1.0000
10:35530122:A:AG	acceptor_gain	1.0000
10:35530123:G:GC	acceptor_gain	1.0000
10:35530123:GA:G	acceptor_gain	1.0000
10:35530123:GAA:G	acceptor_gain	1.0000
10:35530123:GAAA:G	acceptor_gain	1.0000
10:35553186:G:GG	donor_gain	1.0000
10:35566017:TTGCA:T	acceptor_loss	1.0000
10:35566018:TGCAG:T	acceptor_loss	1.0000
10:35566019:GCA:G	acceptor_loss	1.0000

AlphaMissense

2258 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:35337182:C:A	H43Q	1.000
10:35337182:C:G	H43Q	1.000
10:35337184:T:A	I44N	1.000
10:35337184:T:C	I44T	1.000
10:35337184:T:G	I44S	1.000
10:35516590:T:A	V111D	1.000
10:35530184:T:C	F174L	1.000
10:35530186:C:A	F174L	1.000
10:35530186:C:G	F174L	1.000
10:35530199:T:C	F179L	1.000
10:35530201:C:A	F179L	1.000
10:35530201:C:G	F179L	1.000
10:35530209:C:A	A182D	1.000
10:35530215:T:C	L184P	1.000
10:35530226:T:C	C188R	1.000
10:35530228:T:G	C188W	1.000
10:35530230:C:A	A189D	1.000
10:35530236:T:A	V191D	1.000
10:35530242:T:C	L193P	1.000
10:35553022:T:C	Y195H	1.000
10:35553026:T:C	L196P	1.000
10:35553029:A:T	E197V	1.000
10:35553032:G:C	R198T	1.000
10:35553032:G:T	R198I	1.000
10:35553033:A:C	R198S	1.000
10:35553033:A:T	R198S	1.000
10:35553035:T:C	L199P	1.000
10:35553073:T:A	W212R	1.000
10:35553073:T:C	W212R	1.000
10:35553091:G:A	G218R	1.000

dbSNP variants (sampled 300 via entrez): RS1000000981 (10:35565041 T>G), RS1000003738 (10:35483285 A>C), RS1000005399 (10:35482666 G>C), RS1000030286 (10:35352666 G>A), RS1000032177 (10:35565267 C>T), RS1000032584 (10:35456851 C>T), RS1000035710 (10:35539278 A>G), RS1000049592 (10:35436170 G>A), RS1000054615 (10:35266050 T>A), RS1000054865 (10:35304841 A>G), RS1000077998 (10:35346737 C>T), RS1000079422 (10:35483564 T>G), RS1000086523 (10:35380782 G>T), RS1000089412 (10:35303164 G>A), RS1000101495 (10:35435844 A>G)

Disease associations

OMIM: gene MIM:612786 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST000964_19	Ulcerative colitis	7.000000e-10
GCST004131_87	Inflammatory bowel disease	6.000000e-12
GCST004132_106	Crohn’s disease	4.000000e-14
GCST007109_1	Diarrhoea-associated Entamoeba histolytica infection	6.000000e-09
GCST012380_4	Eosinophilic esophagitis	4.000000e-08

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (6): CHEMBL3885550 (PROTEIN COMPLEX), CHEMBL4106161 (PROTEIN COMPLEX), CHEMBL4296115 (PROTEIN COMPLEX), CHEMBL4523634 (PROTEIN COMPLEX), CHEMBL4523637 (PROTEIN COMPLEX), CHEMBL5483184 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 2,635 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL5199065	ISTISOCICLIB	2	21
CHEMBL445813	AT-7519	2	2,614

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs12777960	CCNY		0.00	0

ChEMBL bioactivities

89 potent at pChembl≥5 of 92 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.40	IC50	0.4	nM	CHEMBL4563703
9.10	IC50	0.8	nM	CHEMBL4535078
8.80	IC50	1.6	nM	CHEMBL4446451
8.74	IC50	1.8	nM	CHEMBL4522598
8.59	IC50	2.6	nM	CHEMBL4515515
8.55	IC50	2.8	nM	CHEMBL6144731
8.52	IC50	3	nM	CHEMBL4542127
8.52	IC50	3	nM	CHEMBL4530961
8.47	IC50	3.4	nM	CHEMBL4527767
8.38	IC50	4.2	nM	CHEMBL6144731
8.19	IC50	6.4	nM	CHEMBL4579572
8.00	IC50	10	nM	CHEMBL4580787
8.00	IC50	10	nM	CHEMBL4519165
7.97	IC50	10.7	nM	STAUROSPORINE
7.96	IC50	11	nM	CHEMBL4456492
7.86	IC50	13.8	nM	STAUROSPORINE
7.85	IC50	14	nM	CHEMBL4459422
7.85	IC50	14	nM	CHEMBL4563705
7.79	IC50	16.3	nM	STAUROSPORINE
7.79	IC50	16.1	nM	CHEMBL6144731
7.77	IC50	17	nM	CHEMBL4555069
7.76	IC50	17.2	nM	STAUROSPORINE
7.70	IC50	19.8	nM	AT-7519
7.62	IC50	24	nM	STAUROSPORINE
7.57	IC50	27	nM	CHEMBL4589122
7.47	IC50	34	nM	CHEMBL4473682
7.40	IC50	39.6	nM	CHEMBL4434727
7.39	IC50	41	nM	CHEMBL4584359
7.35	IC50	45	nM	CHEMBL4554744
7.35	IC50	45	nM	CHEMBL4576258
7.32	IC50	48	nM	CHEMBL4544087
7.31	IC50	49	nM	CHEMBL4474689
7.30	IC50	50	nM	CHEMBL4464758
7.29	IC50	51.1	nM	STAUROSPORINE
7.25	IC50	55.6	nM	CHEMBL4848734
7.21	IC50	62	nM	CHEMBL4586749
7.20	IC50	62.7	nM	CHEMBL4856177
7.18	IC50	66.3	nM	STAUROSPORINE
7.17	IC50	68	nM	CHEMBL4583677
7.15	IC50	70.9	nM	STAUROSPORINE
7.14	IC50	72	nM	CHEMBL4466362
7.11	IC50	77	nM	CHEMBL4459085
7.11	IC50	78.4	nM	CHEMBL4848734
7.09	IC50	82	nM	CHEMBL4447871
7.09	IC50	82	nM	CHEMBL4466865
7.08	IC50	83	nM	CHEMBL4556640
7.08	IC50	83.8	nM	STAUROSPORINE
7.06	IC50	88	nM	CHEMBL4580787
7.06	IC50	88	nM	CHEMBL4435761
7.06	IC50	88	nM	CHEMBL4434727

PubChem BioAssay actives

86 with measured affinity, of 260 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[(2,6-dichloro-3-methoxybenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0004	uM
4-[(2-chloro-6-methoxybenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0008	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[3-(prop-2-enoylamino)phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0010	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0010	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0010	uM
4-[(2-fluoro-6-methoxybenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0016	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0018	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0026	uM
4-benzamido-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0030	uM
4-[(2-chloro-6-methoxybenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0030	uM
4-[(2,6-difluorobenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0034	uM
4-[(2,6-dichloro-3-methoxybenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0064	uM
N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-4-[(2,4,6-trichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide	1609466: Competitive irreversible inhibition of CDK16/cyclin Y (unknown origin) in presence of Km ATP	ic50	0.0100	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[4-(prop-2-enoylamino)phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0100	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1715415: Inhibition of human CDK17/cyclin-Y using MBP protein as substrate by [gamma-33P]-ATP assay	ic50	0.0107	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-(propanoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0110	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0140	uM
N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-4-[[2-(2-methoxyphenyl)acetyl]amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0140	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[4-[[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]amino]phenyl]-1H-pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0170	uM
4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0198	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-[[(E)-5-(dimethylamino)pent-2-enoyl]amino]phenyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0270	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[3-[[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]amino]phenyl]-1H-pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0340	uM
N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-4-[(2,4,6-trichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633948: Inhibition of recombinant NanoLuc-tagged CDK14/cyclin Y expressed in human HCT116 cells at 1 uM incubated for 20 to 24 hrs by by NanoBRET assay	ic50	0.0396	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[(3R)-1-[4-[[(E)-5-(dimethylamino)pent-2-enoyl]amino]phenyl]sulfonylpyrrolidin-3-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0410	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-[[(E)-5-(dimethylamino)pent-2-enoyl]amino]phenyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0450	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-(prop-2-enoylamino)benzoyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0450	uM
N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-4-[(2,4,6-trimethoxybenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0480	uM
N-[1-[3-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-4-[(2,4,6-trichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0490	uM
4-[(2,6-dimethoxybenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0500	uM
3-acetyl-7-[[4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-yl]amino]-4-morpholin-4-ylchromen-2-one	1771108: Inhibition of human CDK16/cyclin-Y using RB protein as substrate incubated for 2 hrs by [gamma-33P]-ATP assay	ic50	0.0556	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-(prop-2-enoylamino)phenyl]sulfonylpiperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0620	uM
4-(4-methylpiperazin-1-yl)-N-[4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-yl]quinolin-7-amine	1771107: Inhibition of human CDK14/cyclin-Y using RB protein as substrate incubated for 2 hrs by [gamma-33P]-ATP assay	ic50	0.0627	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[4-[[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]amino]phenyl]-1H-pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0680	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[3-[[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]amino]phenyl]-1H-pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0720	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0770	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0820	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[[3-(propanoylamino)phenyl]methyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0820	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzoyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0830	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.0880	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[[4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]methyl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1080	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[(3R)-1-[4-[[(E)-5-(dimethylamino)pent-2-enoyl]amino]phenyl]pyrrolidin-3-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1170	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[4-(prop-2-enoylamino)benzoyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1260	uM
N-[5-[[4-[[(3R,3aR,6R,6aR)-3-methoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-5-chloropyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]phenyl]prop-2-enamide	1885424: Inhibition of human CDK16/cyclin-Y protein-protein complex	ic50	0.1350	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[(3R)-1-[(E)-4-(dimethylamino)but-2-enoyl]piperidin-3-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1480	uM
N-[(3R)-1-[[3-[[(E)-but-2-enoyl]amino]phenyl]methyl]pyrrolidin-3-yl]-4-[(2,6-dichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1510	uM
N-[1-[4-[[(E)-but-2-enoyl]amino]phenyl]piperidin-4-yl]-4-[(2,6-dichlorobenzoyl)amino]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1540	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[4-[[4-(prop-2-enoylamino)benzoyl]amino]phenyl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1690	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[[3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]phenyl]methyl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.1830	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[1-[(E)-4-(dimethylamino)but-2-enoyl]piperidin-4-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.2080	uM
4-[(2,6-dichlorobenzoyl)amino]-N-[(3R)-1-[3-[[(E)-5-(dimethylamino)pent-2-enoyl]amino]phenyl]pyrrolidin-3-yl]-1H-pyrazole-5-carboxamide;2,2,2-trifluoroacetic acid	1633939: Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assay	ic50	0.2180	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	4
Benzo(a)pyrene	decreases expression	3
Tobacco Smoke Pollution	increases methylation, affects expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	increases abundance, affects cotreatment, increases oxidation	1
bisphenol A	affects cotreatment, decreases methylation	1
salinomycin	decreases expression	1
cobaltous chloride	decreases expression	1
benzo(e)pyrene	affects methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Ethanol	affects cotreatment, decreases expression, increases abundance	1
Caffeine	affects phosphorylation	1
Carbamazepine	affects expression	1
Cisplatin	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Hydrogen Peroxide	affects expression	1
Ivermectin	decreases expression	1

ChEMBL screening assays

196 unique, capped per target: 196 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3632296	Binding	Inhibition of CDK16/cyclin Y (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity. — Bioorg Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SH52	HAP1 CCNY (-) 1	Cancer cell line	Male
CVCL_SH53	HAP1 CCNY (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.